The primary end-points of this study included the allergen-induced LAR on day 84 assessed by LAR AUC3–7h and LAR%, and the safety and tolerability of daily ecleralimab administration assessed by AEs and SAEs. Secondary end-points included day 42 and day 84 EAR AUC0–2h, EAR%, EARmin and LARmin, and day 42 LAR AUC3–7h and LAR%. Exploratory end-points included sputum eosinophils, FENO, methacholine PC20 and blood eosinophil levels.
Partial Protocol Preview
This section provides a glimpse into the protocol. The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Gauvreau G.M., Hohlfeld J.M., FitzGerald J.M., Boulet L.P., Cockcroft D.W., Davis B.E., Korn S., Kornmann O., Leigh R., Mayers I., Watz H., Grant S.S., Jain M., Cabanski M., Pertel P.E., Jones I., Lecot J.R., Cao H, & O'Byrne P.M. (2023). Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. The European Respiratory Journal, 61(3), 2201193.
Other organizations :
McMaster University, Fraunhofer Institute for Toxicology and Experimental Medicine, Medizinische Hochschule Hannover, University of British Columbia, Université Laval, University of Saskatchewan, University of Calgary, University of Alberta, LungenClinic Grosshansdorf, German Center for Lung Research, Novartis (United States), Novartis (Switzerland)
Allergen-induced LAR on day 84 assessed by LAR AUC3–7h and LAR%
Safety and tolerability of daily ecleralimab administration assessed by AEs and SAEs
Day 42 and day 84 EAR AUC0–2h, EAR%, EAR min and LAR min
Day 42 LAR AUC3–7h and LAR%
Sputum eosinophils
Methacholine PC20
Blood eosinophil levels
control variables
Not explicitly mentioned
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to
get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
